Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9228214rdf:typepubmed:Citationlld:pubmed
pubmed-article:9228214lifeskim:mentionsumls-concept:C0229664lld:lifeskim
pubmed-article:9228214lifeskim:mentionsumls-concept:C0011615lld:lifeskim
pubmed-article:9228214lifeskim:mentionsumls-concept:C0023517lld:lifeskim
pubmed-article:9228214lifeskim:mentionsumls-concept:C0038585lld:lifeskim
pubmed-article:9228214lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:9228214pubmed:issue4lld:pubmed
pubmed-article:9228214pubmed:dateCreated1997-9-16lld:pubmed
pubmed-article:9228214pubmed:abstractTextSubstance P has various immunomodulatory effects, including in vitro modification of lymphocyte proliferation and cytokine release. Elevated levels of substance P and increased staining of substance P-positive nerve fibres have been reported in atopic dermatitis patients. We examined fluoresceinated substance P binding to a range of lymphocyte subsets and compared the results in atopic dermatitis, non-atopic psoriasis patients and normal controls. Fluoresceinated substance P and phycoerythrin-labelled monoclonal antibodies to CD3, CD4, CD8, CD57, CD19 and CD14 were incubated in duplicate with Ficoll-Hypaque separated peripheral blood mononuclear leukocytes. With flow cytometry the fluoresceinated substance P-positive cells were identifiable as a peak of positively fluorescent cells, and the percentages of positive cells were measured. We have demonstrated binding of fluoresceinated substance P to all subsets examined, with significantly less binding to atopic dermatitis CD3-, CD8- and CD57-positive cells. This may affect cytokine release and hence be important in the pathogenesis of atopic dermatitis.lld:pubmed
pubmed-article:9228214pubmed:languageenglld:pubmed
pubmed-article:9228214pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9228214pubmed:citationSubsetIMlld:pubmed
pubmed-article:9228214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9228214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9228214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9228214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9228214pubmed:statusMEDLINElld:pubmed
pubmed-article:9228214pubmed:monthJullld:pubmed
pubmed-article:9228214pubmed:issn0001-5555lld:pubmed
pubmed-article:9228214pubmed:authorpubmed-author:GordonD JDJlld:pubmed
pubmed-article:9228214pubmed:authorpubmed-author:PereiraR SRSlld:pubmed
pubmed-article:9228214pubmed:authorpubmed-author:HoldenC ACAlld:pubmed
pubmed-article:9228214pubmed:authorpubmed-author:RustinM HMHlld:pubmed
pubmed-article:9228214pubmed:authorpubmed-author:OstlereL SLSlld:pubmed
pubmed-article:9228214pubmed:authorpubmed-author:AyliffeM JMJlld:pubmed
pubmed-article:9228214pubmed:issnTypePrintlld:pubmed
pubmed-article:9228214pubmed:volume77lld:pubmed
pubmed-article:9228214pubmed:ownerNLMlld:pubmed
pubmed-article:9228214pubmed:authorsCompleteYlld:pubmed
pubmed-article:9228214pubmed:pagination260-3lld:pubmed
pubmed-article:9228214pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:meshHeadingpubmed-meshheading:9228214-...lld:pubmed
pubmed-article:9228214pubmed:year1997lld:pubmed
pubmed-article:9228214pubmed:articleTitleSubstance P binding to peripheral blood mononuclear leukocytes in atopic dermatitis.lld:pubmed
pubmed-article:9228214pubmed:affiliationDepartment of Dermatology, St Helier N.H.S. Trust, Surrey, UK.lld:pubmed
pubmed-article:9228214pubmed:publicationTypeJournal Articlelld:pubmed